Novartis Aims To Leap-Frog Into Next Immuno-Oncology Wave With Aduro
This article was originally published in The Pink Sheet Daily
Executive Summary
Novartis hopes its multi-year deal with Aduro Biotech to develop molecules to unlock dormant immune cells by targeting and activating a central signaling pathway called STING will allow it to make up for lost time and catch “the next wave” in immuno-oncology.
You may also be interested in...
Aduro Says End Of Janssen Collaborations “Not A Lethal Blow”
Both Janssen and Aduro gradually realized the Listeria technology platform was not delivering hoped-for results. Aduro will not continue the projects abandoned by Janssen, and will focus on its STING and APRIL programs going forward.
Where Does Novartis Go From Here In Oncology? A Conversation With Its Oncology, Gene Therapy Execs
Novartis may be behind other big rivals that already have immuno-oncology therapies on the market but its top R&D scientists Alessandro Riva and Usman Azam say it can leap frog to a front position using its early IO pipeline and targeted cancer drugs.
Biopharma Quarterly Dealmaking Statistics, Q1 2015
Biopharma financing reached $15.1 billion, with record-breaking FOPO dollar volume making up close to $10 billion of the total; AbbVie topped the $66.5 billion M&A activity with its $20 billion buy of Pharmacyclics; and gastroenterology was one of the most highly partnered therapeutic areas.